Atorvastatin/ezetimibe 복합제 복용 후 발생한 시야결손 부작용 사례보고Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study
- Other Titles
- Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study
- Authors
- 지은희
- Issue Date
- 2019
- Publisher
- 한국임상약학회
- Keywords
- Atorvastatin; visual field defect; adverse drug reaction; causality assessment
- Citation
- 한국임상약학회지, v.29, no.2, pp.133 - 137
- Journal Title
- 한국임상약학회지
- Volume
- 29
- Number
- 2
- Start Page
- 133
- End Page
- 137
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/2454
- DOI
- 10.24304/kjcp.2019.29.2.133
- ISSN
- 1226-6051
- Abstract
- Atorvastatin is one of the most widely prescribed medications for dyslipidemia treatment. In Korea, post combined therapy with ezetimibe, a 73-year-old woman was reported by a community pharmacy to have experienced visual field defect, which recovered after drug discontinuation. She had never experienced this symptom before, and several studies have reported an association between use of statins and visual disorders such as blurred vision, diplopia, and cataract. Blockage of cholesterol accumulation, oxidative stress, or myopathy is expected to be a cause of this symptom. Naranjo scale, Korean causality assessment algorithm (Ver.2), and World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria were the three tools used to determine causality between the visual disorder and atorvastatin. The results represent ‘probable’, ‘certain’, and ‘probable/likely’ causality, respectively. Our results, in combination with a review of literature, indicate that ocular adverse effects are highly likely related to atorvastatin
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/2454)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.